
A prostate cancer detection software system, to help pathologists quickly identify suspicious areas of tissue, has won government funding. The …

The NHS has announced that artificial pancreases will be available to patients with type 1 diabetes, with up to 1,000 …

Biogen’s Phase II study for gosuranemab, an anti-tau antibody for Alzheimer’s disease, did not meet its primary endpoint, and has …

The MHRA has granted marketing authorisation (MA) for Ontozry (cenobamate) for the treatment of focal-onset seizures in adult patients with …

Care home staff vaccinations to be compulsory COVID-19 vaccinations among care home staff are to become mandatory, the Guardian has …

The past week has seen quite a mixed bag when it comes to COVID-19 news, an AstraZeneca antibody has failed …

Results from Regeneron’s Recovery trial, investigating a potent monoclonal antibody combination treatment in hospitalised patients with severe COVID-19, have shown …

ACTEGA has officially launched Signite, a new decorating solution designed to significantly reduce waste in label production. The hope is …

Avadel’s Phase III trial for FT218 in patients with narcolepsy has shown positive results. The data from the trial demonstrated …

AstraZeneca has failed to reach the primary endpoint in their Storm Chaser trial, assessing the safety and efficacy of AZD7442, …

Novo Holdings, a holding company of the Novo Group, has acquired BBI Group from Exponent for an enterprise value of …

Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia did not meet its primary …

Belgian clinical stage company, Novadip Biosciences, has announced positive results from its Phase I trial of its autologous cell-based osteogenic …

Cognito Therapeutics are going to run a second digital therapeutic study evaluating individuals who have the genetic rare disease, Down …

Janssen has announced positive data from its Phase III GLOW study, with the combination of imbruvica (ibrutinib) plus venetoclax (I+V) …

A senior executive at the EMA recommended abandoning the use of the AstraZeneca vaccine in the EU where alternatives are …

NICE has recommended BMS’s nivolumab plus ipilimumab (also known as Opdivo and Yervoy) to treat people with a rare form …

Celltrion has announced positive top-line data for its experimental antibody COVID-19 treatment, with Phase III trials finding it safe and …

Germany’s health ministry has demanded that J&J must deliver 6.5 million COVID-19 vaccine doses to Germany in July to make …